INTERIM REPORT JANUARY – SEPTEMBER 2015

For the July-September period

  · Net sales for the period were SEK 32.2 million (32.4).
  · Operating income (EBIT) for the period was SEK 5.1 million (7.3).
  · Operating margin for the period was 16 percent (22).
  · Earnings after tax for the period were SEK 3.6 million (6.4).
  · Earnings per share for the period, basic and diluted, were SEK 0.03 (0.05).
  · Net sales for the period were SEK 99.8 million (94.5).
  · Operating income (EBIT) for the period was SEK 15.1 million (13.4).
  · Operating margin for the period was 15 percent (14).
  · Earnings after tax for the period were SEK 9.5 million (8.0).
  · Earnings per share for the period, basic and diluted, were SEK 0.08 (0.06).

For the January-September period

  · Net sales for the period were SEK 99.8 million (94.5).
  · Operating income (EBIT) for the period was SEK 15.1 million (13.4).
  · Operating margin for the period was 15 percent (14).
  · Earnings after tax for the period were SEK 9.5 million (8.0).
  · Earnings per share for the period, basic and diluted, were SEK 0.08 (0.06).


Significant events in the third quarter and after the balance sheet date.

  · No significant events occurred in the third quarter or after the balance
sheet date.


President and CEO Anders Karlsson’s comments on the third quarter 2015:
“Sales and profitability continued to increase cumulatively for the year and we
are seeing an improvement in our operating margin, despite having to compare to
a strong third quarter last year. For the first three quarters EBIT rose to 15
percent (14), while the corresponding figure for the third quarter was 16
percent (22). It is gratifying to see such strong performance in the U.S., where
sales were up across the board for our key products. The extensive efforts we
focused on the American market, initiated in 2014, are now bearing results in
the form of increased sales. We now look forward with confidence to the launch
of our new product QTYPE®, based on real-time PCR methodology. Our product
concept was most recently presented at the end of September at the main HLA
typing congress for the American market. Active sales of QTYPE® are expected to
commence in early 2016.”

For more information please contact:
Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail:
anders.karlsson@allenex.se
Yvonne Axelsson, CFO Allenex AB, and ph.: +468-508 939 72, e-mail:
yvonne.axelsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities
Markets Act and /or the Financial Instruments Trading Act. The information was
submitted for publication on Nov 27, 2015, at 08.30 CET.  Allenex is a life
science-company that develops, manufacture, market and sell products for safer
transplants of organs and bone marrow on the global market. Allenex is listed on
NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 55 persons are employed in the
Allenex group.